News

SAIC-Frederick has signed a contract with GenVec for the development of influenza and HIV vaccines in support of the Vaccine Research Center (VRC) of the National Institute of

Amgen has reported that the Phase 3 PRIME 203 trial evaluating Vectibix (panitumumab) administered in combination with Folfox (an oxaliplatin-based chemotherapy) as a first-line treatment of metastatic colorectal

Ligand Pharmaceuticals has extended its research collaboration with Pfizer for JAK3 by one year. The research and license agreement entered with Wyeth provided for an initial three year

Phase Forward has entered into a multi-year agreement with Quotient Clinical, a strategic business unit of Quotient Bioresearch (Quotient). Quotient is implementing Phase Forward’s InForm Global Trial Management

The study is designed to evaluate the effect of anti-inflammatory treatment in type 1 diabetes patients after the initial period of autoimmune activity that results in the loss

Pennsaid Topical Solution is a non-steroidal anti-inflammatory drug used for the treatment of the signs and symptoms of osteoarthritis of the knee. Dan Chicoine, chairman of Nuvo Research,

Catalent Pharma Solutions (Catalent) has entered into a strategic alliance with Endotis Pharma for the development of oral formulations of synthetic oligosaccharides. Using Catalent’s drug delivery technologies, the

Aureus Pharma has extended its knowledge database agreement with sanofi-aventis research & development for an additional three-year term. Under the agreement, Aureus will provide new AurSCOPE knowledge databases

This four-year contract has a total value of over $22m if all options are exercised. Over the next year, GenVec will receive approximately $2.6m. Under the contract, the